A digital illustration of a double helix intertwined with a pink ribbon, symbolizing genetic connections to breast cancer awareness.

Decoding Breast Cancer Risk: Can Your Genes Predict Recurrence?

Mira Elwood in Health & Wellness October 2026 • 4 min read.

"New research identifies a genetic marker that could help personalize breast cancer treatment and improve outcomes, especially for those with triple-negative breast cancer."

Breast cancer is a complex disease, influenced by a mix of genetic and environmental factors. While we've made strides in identifying genes that increase susceptibility, predicting which women will experience a recurrence remains a challenge. This is crucial because relapse is a major driver of mortality in breast cancer patients.

Chemokines and their receptors play a significant role in cancer progression. Chemokine decoy receptors (CDRs) act as scavengers, essentially neutralizing chemokines that can promote tumor growth and spread. Two key CDRs, DARC and CCBP2, have been found to play a protective role in breast cancer.

This article delves into a study that investigates how variations in the genes encoding DARC and CCBP2 might affect breast cancer recurrence. By understanding these genetic nuances, we could potentially refine treatment strategies and improve long-term survival, particularly for aggressive subtypes like triple-negative breast cancer (TNBC).

AI Search Multiple angles on this topic

Stats & Impact

Breast Diversity and Appearance

Mamamia presents photographs of more than 50 different women's breasts after Ellie Sedgwick's years of self-hate. Refinery29 features 24 women discussing their breasts alongside unedited, real photographs. Together, these projects explore the varied appearance of breasts and the complex relationship many women have with them.

The Genetic Link: How DARC rs12075 Impacts Recurrence Risk

A digital illustration of a double helix intertwined with a pink ribbon, symbolizing genetic connections to breast cancer awareness.

Researchers analyzed two specific single nucleotide polymorphisms (SNPs) – rs12075 in the DARC gene and rs2228468 in the CCBP2 gene – in a group of 806 women with primary breast cancer. They wanted to see if these genetic variations were linked to recurrence-free survival (RFS), meaning the length of time after treatment before the cancer returned.

The study revealed a significant association between the rs12075 SNP in DARC and recurrence risk. Women with the GG genotype at this location had a higher risk of recurrence compared to those with AG or AA genotypes. This suggests that the rs12075 variant could serve as a predictive marker.

rs12075 (DARC): Patients with the GG genotype showed a statistically significant higher recurrence risk (HR = 0.54, P = 0.027).
rs2228468 (CCBP2): No significant association was found between this SNP and relapse risk (HR = 0.80, P = 0.222).

AI Search Multiple angles on this topic

Latest Research

ACKR1 and Breast Cancer Research

Research on chemokine receptors continues to examine their roles in tumor development and progression, but the precise mechanisms underlying ACKR1's involvement remain incompletely understood. One review reports that the rs12075 polymorphism in ACKR1 has been linked to worse relapse-free survival in patients with triple-negative breast cancer and to lymph node metastasis in patients with breast cancer. Another source notes that studies have identified a critical role for DARC polymorphism in breast cancer, although it does not establish a specific clinical outcome.

Counterpoints

Limits of Genetic Risk Findings

The cited study reports that two nonsynonymous SNPs, rs12075 (G42D) in DARC and rs2228468 (S373Y) in CCBP2, were examined in relation to breast cancer recurrence risk. These variants were significantly correlated with lymph node metastasis under a dominant model, but not under a recessive model. The findings suggest that genetic polymorphisms in genes encoding chemokine decoy receptors may influence metastatic risk, while also showing that the observed association depends on the genetic model used.

Interestingly, when the researchers looked at different breast cancer subtypes, the association between rs12075 and recurrence was particularly strong in women with triple-negative breast cancer (TNBC). This aggressive subtype often has limited treatment options, making the identification of predictive markers like rs12075 especially valuable. In TNBC patients, the GG genotype was linked to a significantly shorter recurrence-free survival (HR = 0.22, P = 0.021).

The Future of Personalized Breast Cancer Treatment

This research suggests that the rs12075 variant in the DARC gene could be a valuable tool for predicting recurrence risk in breast cancer, especially in TNBC. This information could help doctors personalize treatment plans, potentially leading to better outcomes.

However, it's important to remember that this is just one study, and more research is needed to confirm these findings in larger and more diverse populations. Future studies should also explore how rs12075 interacts with other genetic and clinical factors to influence recurrence risk.

Ultimately, the goal is to develop comprehensive genetic profiles that can accurately predict an individual's risk of breast cancer recurrence and guide treatment decisions. By understanding the complex interplay of genes and cancer, we can move towards a future of truly personalized medicine, improving the lives of women affected by this disease.

What keeps the recurrence result unsettled

After adjustment for lymph node status and tumor size, the TNBC result was borderline and did not meet conventional statistical significance.^[1]
The authors state that more eligible patients and additional survival outcomes are needed to assess the SNPs’ prognostic value.^[2]

The recurrence study at a glance

Population	Patients with primary breast cancer^[1]
Sample size	806^[1]
Setting	Shanghai Cancer Center of Fudan University^[1]
Duration	Median follow-up time was 48 months^[1]
Main outcome	Recurrence-free survival (RFS)^[1]
Conflicts of interest	No conflict of interest^[1]
Times cited	9^[1]

How related breast cancer studies compare

A later review cited rs12075 as linked to worse relapse-free survival in TNBC and to lymph node metastasis in breast cancer; it also noted that the mechanisms behind ACKR1’s role in tumors remain unclear.^{[3] [4]}

What remains unanswered about these variants

Do larger patient groups reproduce the recurrence association when survival outcomes and clinical characteristics are considered together?^{[1] [2]}

Sources

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1002/cam4.1823, Alternate LINK

Title: Effect Of Functional Genetic Variants In Chemokine Decoy Receptors On The Recurrence Risk Of Breast Cancer

Subject: Cancer Research

Journal: Cancer Medicine

Publisher: Wiley

Authors: Dou-Dou Li, Chen Yang, Zhi-Ming Shao, Ke-Da Yu

Published: 2018-10-24

Everything You Need To Know

What is the significance of the DARC gene in relation to breast cancer?

The DARC gene, specifically the rs12075 variant, is a genetic marker that has been linked to breast cancer recurrence risk. The study found that women with the GG genotype at the rs12075 location in the DARC gene had a higher risk of recurrence compared to those with the AG or AA genotypes. This is significant because identifying such markers can help predict which patients are more likely to experience a relapse, particularly in aggressive subtypes like triple-negative breast cancer (TNBC).

What are chemokine decoy receptors (CDRs) and how do they relate to the research?

Chemokine decoy receptors (CDRs), such as DARC and CCBP2, are proteins that play a protective role in breast cancer by neutralizing chemokines, which can promote tumor growth and spread. The study focused on variations in the genes encoding these CDRs. Understanding the genetic nuances of DARC and CCBP2 could help refine treatment strategies and improve long-term survival for patients.

What specific genetic variations were analyzed and what were the findings?

The rs12075 SNP in the DARC gene showed a significant association with recurrence risk. Women with the GG genotype at this location had a higher risk of recurrence. The rs2228468 SNP in the CCBP2 gene did not show a significant association with relapse risk.

Which breast cancer subtype showed the strongest link to the rs12075 variant?

The rs12075 variant's association with recurrence was particularly strong in patients with triple-negative breast cancer (TNBC). In TNBC patients, the GG genotype of rs12075 was linked to a significantly shorter recurrence-free survival. TNBC is an aggressive subtype often with limited treatment options, making predictive markers like rs12075 especially valuable.

How could this research change breast cancer treatment?

The findings suggest the rs12075 variant in the DARC gene could be used to predict recurrence risk in breast cancer, especially in TNBC. This information can help doctors personalize treatment plans. This could mean tailoring therapies based on a patient's genetic profile, potentially leading to more effective treatments and improved outcomes.